65,437 trials
Alzheimer Disease
Primary: Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change…
Bipolar Disorder
Primary: Proportion of Participants Not Experiencing Relapse Through Week 52 in the Double-Blind Relapse Assessment Phase (Phase 2) — 1.00; 1.00; 0.98; 0.98 Proportion of…
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Percent (%) Absolute Change in Fructosamine — 5.5; 4.9 Percent absolute change — p=0.506
Staphylococcal Infections
Primary: Number of Vaccine-related Serious Adverse Experiences Following Vaccination — 0; 0; 0; 0 Participants
Gingival Diseases
Primary: Dental Plaque — 2.273; 1.806; 2.041 Units on a scale — p=<0.05
Glaucoma, Open Angle · Ocular Hypertension
Primary: Stinging on Instillation — 0.6; 1.0; 0.6 Units on a scale
Tobacco Dependence
Primary: Maximum Plasma Concentration — 15.43; 16.49; 30.07; 27.07 (ng/ml)
Myopia
Primary: Lens Awareness — 8; 9 Participants
HIV · Infectious
Primary: Number of Viral Load (VL) < 50 HIV-1 RNA Copies/mL (Time to Loss of Virologic Response[TLOVR]) Subjects by Sex — 146; 83 participants — p=0.30
Myopia
Primary: Overall Lens Satisfaction — 7.5; 7.5 Units on a scale
Metastatic Pancreatic Cancer
Primary: Percentage of Participants Surviving at 6 Months — 57.4 percentage of participants
Bradycardia · Arrhythmia
Primary: Percentage of Participants With First Diagnosis of Clinically Actionable Events (CAE) at 12 Months — 35; 47 Percentage of participants — p=<0.0001
Asthma
Primary: Mild Exacerbation Rate (OFF-LABA) (Change From Baseline) — -0.16; 0.04 Exacerbations/Subject/Week
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 32 — -1.86; -1.39 Percent of glycosylated hemoglobin (A1C) — p=<0.001
Follicular Lymphoma
Primary: Progression-free Survival — 59 percent chance of PFS at 5 years